Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oncology and obesity. Its primary pipeline assets include CRB-701, an antibody-drug conjugate (ADC) for Nectin-4-expressing tumors, and CRB-913, an oral CB1 inverse agonist for obesity. The company has no product revenue and relies on equity financing and investment income.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(22.97) million | $(16.98) million |
| Net Loss Per Share (Basic/Diluted) | $(1.23) | $(1.39) |
| Operating Expenses | $24.30 million | $19.78 million |
| Research & Development (R&D) | $19.82 million | $15.64 million |
| General & Administrative (G&A) | $4.49 million | $4.13 million |
| Cash, Cash Equivalents, & Investments | $138.22 million | $163.27 million |
| Net Cash Used in Operating Activities | $(25.57) million | $(16.42) million |
| Accumulated Deficit | $(578.40) million | $(493.87) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $6.0 million year-over-year, driven primarily by higher R&D spending.
- R&D Expense Growth: R&D expenses rose 27% to $19.8 million. This was due to increased clinical costs for CRB-701 (Phase 1/2 enrollment) and CRB-913 (initiation of Phase 1b study), partially offset by a reduction in CRB-601 costs as that program was deprioritized.
- Investment Income Decline: Total other income decreased by 52% to $1.3 million. This was largely due to the absence of a $1.1 million employee retention credit recorded in Q1 2025.
- Share Count Increase: Weighted average shares outstanding increased from 12.2 million to 18.7 million, reflecting a public offering in late 2025 and subsequent vesting of restricted stock units.
Outlook, Risks, and Unusual Items
- Liquidity: Management expects cash and investments of $138.2 million to fund operations for at least 12 months from the filing date. A new shelf registration statement effective March 20, 2026, allows for the sale of up to $300 million in securities.
- Subsequent Events:
- ATM Sales: Between April 1, 2026, and the filing date, the company sold 872,917 shares via its Open Market Sale Agreement, raising approximately $8.9 million in net proceeds.
- Milestone Payment: In April 2026, the company paid a $10.0 million development milestone to CSPC Megalith Biopharmaceutical Co., Ltd. related to CRB-701.
- Lease Amendment: The company entered into a lease amendment in April 2026 to reduce office space and extend the lease term through 2032.
- Risks: The company has a history of operating losses and will require significant additional capital to advance clinical trials. There is no guarantee that funding will be available on acceptable terms. Clinical development carries inherent risks of failure, and regulatory approval is not assured.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $138.2 million cash balance against the burn rate of ~$25.6 million per quarter, considering the recent $10 million milestone payment.
- CRB-701 Progress: Monitor upcoming data presentations at the 2026 ASCO Annual Meeting regarding the Phase 1/2 study and the initiation of the registrational study in HNSCC.
- CRB-913 Data: Track the completion of the Phase 1b "CANYON-1" study expected in summer 2026 to validate the weight loss mechanism and safety profile.
- Dilution Risk: Assess the impact of the active $300 million shelf registration and the recent ATM sales on future share count and per-share value.
- Milestone Obligations: Review the remaining potential milestone payments under license agreements (up to $130 million for CSPC, $150.8 million for UCSF, and $18.0 million for Jenrin) which could impact future cash flow.